U.S. stocks closed another record-setting week with a muted performance. The S&P 500 edged down by 0.1% Friday from its ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
Average premiums and benefits for Medicare's prescription drug program and private Medicare plans are projected to remain ...
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
U.S. stock indexes are drifting around their records Friday as hopes hold that the economy can pull off the rare feat of ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...
An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 ...
The U. S. Food and Drug Administration (FDA) has signed off on Cobenfy, the first revolutionary treatment for schizophrenia ...
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback